Amgen Inc.
AMGNAmgen is a cash-rich biotech giant whose future depends on turning scientific bets into the next generation of long-lived blockbuster drugs.
Because in biotech, durability is everything, and Amgen has been playing that game for decades.
Business Model
Patented biologic drugs
It develops and sells complex, patent-protected medicines that treat serious diseases.
Economic Engine
High-margin drug sales
A 70.8 percent gross margin shows the pricing power of its patented therapies.
Long-Term Lens
Pipeline replacement cycle
The key question is whether new drugs can replace revenue from aging ones over decades.
On this page
Company Story
How do Amgen Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A high-margin drug franchise with real staying power, but only if it keeps refilling its pipeline as older blockbusters fade.”
What does Amgen Inc. actually do?
Amgen discovers, develops, manufactures, and sells biologic medicines for serious diseases.
- Creates treatments for cancer, heart disease, bone disorders, and inflammatory conditions
- Runs large clinical trials to prove safety and effectiveness
- Manufactures complex biologic drugs in its own facilities
Why it matters
Life-saving products with pricing power
Drugs that treat serious diseases can command strong pricing, supporting 70.8 percent gross margins.
How does Amgen Inc. make money?
Amgen makes money by selling patented medicines to hospitals, pharmacies, and healthcare systems around the world.
- Earns revenue from branded biologic drugs protected by patents
- Benefits from multi-year treatment regimens that create repeat sales
- Uses global distribution to sell into major healthcare markets
Economic clue
Strong operating margins
A 29.1 percent operating margin shows that after research and manufacturing, the core business is highly profitable.
Why do long-term investors keep Amgen Inc. on the radar?
Amgen sits at the intersection of aging populations, chronic disease, and biotechnology innovation.
- Global populations are aging, increasing demand for cancer and heart disease treatments
- Biologic drugs are complex and hard to copy, offering longer revenue tails
- Strong cash generation funds future research and acquisitions
Investor takeaway
Cash funds the future
Free cash flow is about 1.05 times net income, meaning reported profits largely turn into real cash to reinvest.
Based on company financial statements.
Benchmark Comparison
How has Amgen Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,623
+62.3% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| AMGN | +62.3% | $1,623 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Amgen Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to long-term healthcare demand driven by aging populations
- A business with 70 percent gross margins and solid cash generation
- A mature biotech that balances innovation with scale
Be Careful If You Expect
- Rapid double-digit growth for decades without volatility
- Immunity from patent expirations or drug competition
- Margins that expand every year without pressure
What To Watch Over Time
- Whether new drugs offset revenue lost to biosimilar competition
- Trends in operating margin, currently 29.1 percent and contracting
- Capital allocation choices, especially large acquisitions and research spending
Key Metrics
Which metrics matter most for Amgen Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
9.1% average annual growth (5 years)
8.5% average annual growth (5 years)
70.8% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 9.1% average annual growth (5 years) | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 8.5% average annual growth (5 years) | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 70.8% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Amgen Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
14.6% ROIC
70.8% gross margin
22.0% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 14.6% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 70.8% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 22.0% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Amgen Inc.?
Amgen Inc. currently appears in these ETF and fund proxies.
QQQ
Invesco QQQ Trust, Series 1
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Amgen Inc.?
Company-specific questions readers often ask about Amgen Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Amgen researches, develops, manufactures, and sells biologic medicines for serious diseases like cancer and heart conditions.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Aging populations globally increase demand for cancer, cardiovascular, and inflammatory treatments, creating a long runway for biologic drug sales.
Biologic manufacturing is complex and capital-intensive, which raises barriers to entry and supports 70.8 percent gross margins.
Strong cash generation, with free cash flow exceeding net income, gives Amgen the financial firepower to invest heavily in research and acquisitions.
A diversified portfolio across multiple disease areas reduces dependence on any single therapeutic category over time.
Bear case
What can break
Patent expirations can quickly erode revenue as biosimilar competitors enter with lower-priced alternatives, compressing margins.
Government pressure on drug pricing in the United States and Europe could structurally reduce profitability over the next two decades.
Research failures are inherent in biotech, and a weak pipeline could leave revenue shrinking as older drugs fade.
Large acquisitions, if mispriced or poorly integrated, could burden the balance sheet without delivering durable growth.
Risk Radar
Key Risks
Where downside pressure can build.
Patent risk: A significant portion of revenue comes from patented drugs that can face steep declines once exclusivity ends.
Pricing risk: Healthcare policy changes in major markets could pressure the current 21.0 percent net margin.
Pipeline risk: Sustaining around 9 percent average annual revenue growth requires successful new drug approvals.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $369.53
- Daily move
- +0.53%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.